1. Home
  2. SXI vs BEAM Comparison

SXI vs BEAM Comparison

Compare SXI & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Standex International Corporation

SXI

Standex International Corporation

HOLD

Current Price

$270.23

Market Cap

3.2B

Sector

Industrials

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$30.24

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SXI
BEAM
Founded
1955
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
2.7B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
SXI
BEAM
Price
$270.23
$30.24
Analyst Decision
Strong Buy
Buy
Analyst Count
3
12
Target Price
$281.33
$50.75
AVG Volume (30 Days)
164.3K
2.0M
Earning Date
04-30-2026
05-05-2026
Dividend Yield
0.51%
N/A
EPS Growth
N/A
82.31
EPS
1.42
N/A
Revenue
$604,535,000.00
$24,000.00
Revenue This Year
$14.87
N/A
Revenue Next Year
$6.07
$32.20
P/E Ratio
$187.94
N/A
Revenue Growth
N/A
33.33
52 Week Low
$128.85
$15.52
52 Week High
$277.35
$36.44

Technical Indicators

Market Signals
Indicator
SXI
BEAM
Relative Strength Index (RSI) 58.66 68.01
Support Level $243.78 $23.71
Resistance Level $277.35 $31.54
Average True Range (ATR) 8.30 1.59
MACD 1.15 0.88
Stochastic Oscillator 79.38 87.74

Price Performance

Historical Comparison
SXI
BEAM

About SXI Standex International Corporation

Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. The company has five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. The maximum revenue is generated from its Electronics segment, which is a component and value-added services provider of both sensing and switching technologies, as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging, among others. Geographically, it derives key revenue from the United States and the rest from the Asia Pacific, Europe, the Middle East, and Africa (EMEA), as well as other regions.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: